Supplemental Table I. Clinical characteristics of all participants according to registration periods

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | Registration periods | | | | | | |
|  |  | The first half period  (June 2007 to May 2013) | | |  | The second half period  (June 2013 to May 2019) | | |
|  |  | Pre-stroke ChEI treatment | | P |  | Pre-stroke ChEI treatment | | P |
|  |  | (+)  (n=80) | (–)  (n=304) |  | (+)  (n=132) | (–)  (n=289) |  |
| Age, years |  | 81.9±6.2 | 81.1±8.1 | 0.41 |  | 84.1±6.5 | 81.8±8.6 | <0.01 |
| Female |  | 47 (58.8) | 154 (50.7) | 0.20 |  | 74 (56.1) | 142 (49.1) | 0.19 |
| Risk factors |  |  |  |  |  |  |  |  |
| Hypertension |  | 66 (82.5) | 243 (79.9) | 0.61 |  | 110 (83.3) | 237 (82.0) | 0.74 |
| Diabetes mellitus |  | 25 (31.3) | 83 (27.3) | 0.48 |  | 38 (28.8) | 76 (26.3) | 0.59 |
| Dyslipidemia |  | 34 (42.5) | 125 (41.1) | 0.82 |  | 64 (48.5) | 151 (52.3) | 0.47 |
| Atrial fibrillation |  | 26 (32.5) | 102 (33.6) | 0.86 |  | 48 (36.4) | 100 (34.6) | 0.73 |
| Ischemic heart disease |  | 11 (13.8) | 56 (18.4) | 0.33 |  | 20 (15.2) | 41 (14.2) | 0.79 |
| Chronic kidney disease |  | 45 (56.3) | 142 (46.7) | 0.13 |  | 78 (59.1) | 139 (48.1) | 0.04 |
| Smoking |  | 26 (32.5) | 133 (43.8) | 0.07 |  | 44 (33.3) | 132 (45.7) | 0.02 |
| Drinking |  | 22 (27.5) | 77 (25.3) | 0.69 |  | 29 (22.0) | 78 (27.0) | 0.27 |
| Pre-stroke medication |  |  |  |  |  |  |  |  |
| Anti-hypertensive |  | 59 (73.8) | 181 (59.5) | 0.02 |  | 99 (75.0) | 154 (53.3) | <0.01 |
| Anti-thrombotic |  | 31 (38.8) | 99 (32.6) | 0.30 |  | 42 (31.8) | 91 (31.5) | 0.95 |
| Anti-diabetic |  | 18 (22.5) | 50 (16.5) | 0.21 |  | 28 (21.1) | 45 (15.6) | 0.16 |
| Statin |  | 14 (17.5) | 47 (15.5) | 0.66 |  | 32 (24.2) | 55 (19.0) | 0.22 |
| Physical and laboratory data |  |  |  |  |  |  |  |  |
| Systolic BP, mmHg |  | 154.7±28.0 | 157.2±29.7 | 0.50 |  | 159.0±28.9 | 161.1±27.0 | 0.46 |
| Body mass index, kg/m2 |  | 21.6±3.1 | 21.7±3.4 | 0.91 |  | 21.8±3.2 | 21.5±3.4 | 0.41 |
| LDL-cholesterol, mmol/L |  | 3.11±0.87 | 2.90±0.81 | 0.04 |  | 2.99±0.95 | 3.03±0.96 | 0.68 |
| Casual blood glucose, mmol/L |  | 7.58±3.48 | 7.63±2.91 | 0.90 |  | 7.67±3.04 | 7.43±2.71 | 0.41 |
| HbA1c, % |  | 6.23±1.01 | 6.19±1.19 | 0.82 |  | 6.22±1.22 | 6.11±1.01 | 0.33 |
| NIHSS on admission |  | 4 [2–8] | 5 [3–11] | 0.053 |  | 5 [2–11] | 4 [2–9] | 0.10 |
| Stroke subtype |  |  |  | 0.64 |  |  |  | 0.37 |
| Cardioembolism |  | 24 (30.0) | 90 (29.6) |  |  | 47 (35.6) | 89 (30.8) |  |
| Large-artery atherosclerosis |  | 16 (20.0) | 68 (22.4) |  |  | 14 (10.6) | 49 (17.0) |  |
| Small-vessel occlusion |  | 16 (20.0) | 74 (24.3) |  |  | 35 (26.5) | 73 (25.3) |  |
| Others |  | 24 (30.0) | 72 (23.7) |  |  | 36 (27.3) | 78 (27.0) |  |
| Acute revascularization |  | 9 (11.3) | 30 ( 9.9) | 0.72 |  | 23 (17.4) | 45 (15.6) | 0.63 |
| Thrombolytic therapy |  | 9 (11.3) | 30 ( 9.9) | 0.72 |  | 18 (13.6) | 37 (12.8) | 0.81 |
| Endovascular thrombectomy |  | 0 ( 0.0) | 1 ( 0.3) | 0.60 |  | 11 ( 8.3) | 19 ( 6.7) | 0.55 |
| Length of hospitalization, day |  | 17.2±8.3 | 16.1±8.8 | 0.33 |  | 16.4±8.0 | 16.7±8.2 | 0.72 |

ChEI: cholinesterase inhibitor, BP: blood pressure, LDL: low-density lipoprotein, HbA1c: hemoglobin A1c. Values are expressed as mean ± SD, median [interquartile range], or n (%).